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Background: Insulin-like growth factor-1 (IGF-1) is the most important physiological regulator of skeletal muscle
progenitor cells, which are responsible for adult skeletal muscle regeneration. The ability of IGF-1 to affect multiple
aspects of skeletal muscle cell biology such as proliferation, differentiation, survival and motility is well recognized,
although the molecular mechanisms implicated in its complex biological action are not fully defined. Since
sphingosine 1-phosphate (S1P) has recently emerged as a key player in skeletal muscle regeneration, we
investigated the possible involvement of the sphingosine kinase (SK)/S1P receptor axis on the biological effects of
IGF-1 in murine myoblasts.
Methods: RNA interference, chemical inhibition and immunofluorescence approaches were used to assess the role
of the SK/S1P axis on the myogenic and mitogenic effects of IGF-1 in C2C12 myoblasts.
Results: We show that IGF-1 increases SK activity in mouse myoblasts. The effect of the growth factor does not
involve transcriptional regulation of SK1 or SK2, since the protein content of both isoforms is not affected; rather,
IGF-1 enhances the fraction of the active form of SK. Moreover, transactivation of the S1P2 receptor induced by
IGF-1 via SK activation appears to be involved in the myogenic effect of the growth factor. Indeed, the pro-
differentiating effect of IGF-1 in myoblasts is impaired when SK activity is pharmacologically inhibited, or SK1 or SK2
are specifically silenced, or the S1P2 receptor is downregulated. Furthermore, in this study we show that IGF-1
transactivates S1P1/S1P3 receptors via SK activation and that this molecular event negatively regulates the mitogenic
effect elicited by the growth factor, since the specific silencing of S1P1 or S1P3 receptors increases cell proliferation
induced by IGF-1.
Conclusions: We demonstrate a dual role of the SK/S1P axis in response to myoblast challenge with IGF-1, that
likely is important to regulate the biological effect of this growth factor. These findings add new information to the
understanding of the mechanism by which IGF-1 regulates skeletal muscle regeneration.
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Sphingosine 1-phosphate (S1P) is a bioactive lipid that is
physiologically present in serum and capable of regulat-
ing multiple essential cellular processes, including cell
growth and survival, cell motility and invasion, angiogen-
esis, lymphocyte trafficking and immune regulation. S1P
is synthesized from sphingosine by a phosphorylation re-
action catalyzed by the sphingosine kinases (SKs) SK1
and SK2, which are highly conserved enzymes activated
by numerous stimuli [1]. S1P levels are tightly regulated
by the balance between biosynthesis catalyzed by SKs, re-
versible conversion to sphingosine mediated by specific
and non-specific lipid phosphatases, and S1P lyase
(SPL)-dependent degradation [2,3]. S1P exerts its func-
tions either as a second messenger or as a ligand of five
specific G-protein coupled receptors named S1P recep-
tors (S1PR). S1PR are differentially coupled to one or
multiple G-proteins and they can activate a variety of
signaling pathways determining distinct and even con-
trasting final cellular effects.
Recently it has emerged that S1P plays a key role in
the biology of skeletal muscle progenitor cells [4]. In-
deed, the bioactive sphingolipid exerts a strong mito-
genic action in satellite cells [5] and also stimulates their
cell motility [6], whereas in myoblasts it behaves as pro-
differentiating [7] and chemorepellant cue [8]. Our re-
cent findings have demonstrated that the S1P signaling
axis, under the control of a number of physiological and
pathophysiological extracellular agents such as tumor
necrosis factor α (TNFα), platelet-derived growth factor
(PDGF) and transforming growth factor β (TGFβ) [9-11],
is the mediator of fundamental biological responses
evoked by the above mentioned agonists. The obtained
results are in keeping with a very complex mechanism of
action of S1P that can have both beneficial and unfavor-
able effects on skeletal muscle regeneration. Indeed, we
have demonstrated that endogenous S1P metabolism, sti-
mulated by SK1 activation and S1P1 engagement, is crit-
ical for myoblast motility and attenuation of the
mitogenic response elicited by PDGF [11]; however, we
have also shown that the SK/S1P axis is exploited by
TGFβ to convey its detrimental pro-fibrotic effect and
that upregulation of S1P metabolism mediated by SK1
together with enhanced expression of S1P3 account for
transdifferentiation of myoblasts into myofibroblasts,
which are responsible for deposition of extracellular
matrix protein [9].
Insulin-like growth factor 1 (IGF-1) is a hormone pep-
tide that, beside being released into the blood from the
liver, can be synthesized by the target tissues, including
skeletal muscle, where IGF-1 concentrations are locally
regulated. IGF-1 plays a key role in skeletal muscle regen-
eration as it is able to stimulate myoblast proliferation
[12]. Moreover, unlike other growth factors, IGF-1 alsostimulates myogenic differentiation and induces myocyte
hypertrophy [12], supporting the notion that IGF-1 is a
master regulator of skeletal muscle biology. These seem-
ingly contradictory roles of the growth factor highlight the
importance of understanding how IGF-1 cooperates with
other mitogenic and differentiating stimuli to induce ei-
ther, or both, these events. In this regard, given the fun-
damental role of IGF-1 in skeletal muscle and its
incompletely defined mechanism of action, we focused
on the possible involvement of the SK/S1P axis on the
biological effect of the growth factor. Data reported here
demonstrate for the first time that IGF-1 activates SKs
in mouse myoblasts. The consequent S1P2 transactiva-
tion appears to be implicated in the myogenic effect of
the growth factor. Moreover, the engagement of S1P1/
S1P3 in IGF-1 signaling, via a mechanism dependent on
SK activation, inhibits myoblast proliferation, which
points to a role for the SK/S1P axis in the control of the
biological outcome of IGF-1 in skeletal muscle.
These results highlight a new role for the SK/S1P axis
in IGF-1-regulated signaling which is important for
the biological response exerted by the growth factor.
This could be exploited to improve skeletal muscle
regeneration.
Methods
Materials
All biochemicals, TRI reagent, cell culture reagents,
DMEM, fetal calf serum, protease inhibitor cocktail,
monoclonal anti-skeletal fast myosin heavy chain (MHC)
(clone MY-32), bovine serum albumin (BSA) were pur-
chased from Sigma-Aldrich (St Louis, MO, USA). Mouse
skeletal muscle C2C12 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA).
Propidium iodide was obtained from Calbiochem (San
Diego, CA, USA). Recombinant IGF-1 was obtained from
PeproTech (London, UK). SKI-2 [2-(p-hydroxyanilino)-4-
(p-chlorophenyl)thiazole] and U0126 were obtained from
Calbiochem. siRNA duplexes corresponding to two DNA
target sequences of mouse SK1 (5’UAGGAACUGUGGC
CUCUAAdTdT3’, 5’GUGUUAUGCAUCUGUUCUAdT
dT3’), mouse SK2 (5′GCCUACUUCUGCAUCUACAdT
dT3′; 5′CCUCAUACAGACAGAACGAdTdT3′), mouse
S1P1 (5′UCACCUACUACUGUUAGAdTdT3′; 5′CUU
GCUAACUAUUUGGAAAdTdT3′), mouse S1P2 (5’CU
CUGUACGUCCGAAUGUAdTdT3’, 5’GACUAAUCA
GAUUGUAGUAdTdT3’), mouse S1P3 (SASI_Mm01_
00145232, SASI_Mm01_00145233), mouse S1P4 (SASI_
Mm01_00094192, SASI_Mm01_00094193), mouse SPL
(SASI_Mm01_00122643) and scrambled siRNA (5′
UUCUCCGAACGUGUCACGUdTdT3′) were obtained
from Sigma-Proligo (The Woodlands, TX, USA). Lipo-
fectamine RNAiMAX was purchased from Invitrogen
(Carlsbad, CA, USA). Enhanced chemiluminescence
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http://www.skeletalmusclejournal.com/content/2/1/15reagents and [γ-32P]ATP (3000 Ci/mmol) were obtained
from GE Healthcare Europe (Milan, Italy). Secondary
antibodies conjugated to horseradish peroxidase, mono-
clonal anti-β-actin and monoclonal anti-myogenin anti-
bodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Monoclonal anti-caveolin-3
antibodies were from BD Biosciences Transduction La-
boratories (Lexington, KY, USA). Specific anti-SK1
polyclonal antibodies (directed against the 16 carboxy-
terminal amino acids of the mouse SK1) [13] were
kindly provided by Dr Y Banno (Gifu University School
of Medicine, Gifu, Japan). Rabbit polyclonal antibodies
generated against SK2 [14] were a kind gift from Dr S0 10 20 3
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Figure 1 Effect of insulin-like growth factor-1 on sphingosine kinase a
incubated with 50 ng/ml insulin-like growth factor-1 (IGF-1) for the indicate
determine sphingosine kinase (SK) activity. Data represent the mean± SEM
duplicate. The effect of IGF-1 in challenged versus unchallenged cells was s
of SK1 (upper panel) and SK2 (lower panel) were performed in membrane
independent experiments are shown. The histograms represent densitome
expressed as -fold increase of the membrane:cytosol ratio. The increase of S
significant by Student’s t-test (*P< 0.05).Nakamura (Department of Molecular and Cellular Biology,
Kobe University Graduate School of Medicine, Kobe, Japan).
Phospho-human SK1 specific polyclonal antibodies (direc-
ted against the phosphopeptide CGSKTPApSPVVVQQ
centered around phospho-Ser225 of human SK1) [15] were
kindly provided by Dr S Pitson (Hanson Institute, institute
of Medical and Veterinary Science, Adelaide, Australia).
Fluorescein-conjugated horse anti-mouse secondary anti-
bodies were obtained from Vector Laboratories (Burlin-
game, CA, USA). Specific polyclonal rabbit anti-mouse SPL
antibodies (directed against the C-terminal peptide 551-
TTDPVTQGNQMNGSPKPR-568) [16] were a kind gift
from Dr RL Proia (National Institute of Diabetes and0 40 50 60
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ctivity and subcellular localization. Serum-starved myoblasts were
d time intervals. (A) Aliquots of cell extracts (40 μg) were used to
of at least three independent experiments, each performed at least in
tatistically significant by Student’s t test (*P< 0.05). (B) Western analysis
and cytosolic fractions. Blots representative of at least three
tric analysis of three independent experiments. Data reported are
K1 and SK2 membrane content induced by IGF-1 was statistically
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http://www.skeletalmusclejournal.com/content/2/1/15Digestive and Kidney Disease, National Institute of Health,
Bethesda, USA). All reagents and probes required to per-
form real-time PCR were from Applied Biosystems (Foster
City, CA, USA). [3H]thymidine (20 Ci/mmol) was from
Perkin Elmer (Waltham, MA, USA).
Cell culture
Murine C2C12 myoblasts were routinely grown in
DMEM supplemented with 10% fetal calf serum, 2 mMA
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Figure 2 Sphingosine kinase-1 phosphorylation induced by insulin-lik
was performed using specific anti-phospho-sphingosine kinase (SK)1 antibo
myoblasts treated with 50 ng/ml insulin-like growth factor-1 (IGF-1) for the
independent experiments with analogous results is shown. The histogram
Data reported are expressed as -fold increase of the membrane:cytosol ratio
was statistically significant by Student’s t test (*P< 0.05). (B) Serum-starved
inhibitor (5 μM U0126) before being challenged with 50 ng/ml IGF-1 for 10
immunoblotted using specific anti-phospho-SK1 and anti-β-actin antibodie
shown. In the histogram band intensity corresponding to phosphorylated S
independent experiments, -fold change over control (set as 1). SK1 phosph
pre-incubation (Student’s t test, #P< 0.05).L-glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin at 37°C in 5% CO2. For myogenic differentiation
experiments, cells were seeded in p35 plates, and when
90% confluent they were shifted to DMEM without
serum containing 1 mg/ml BSA. For proliferation experi-
ments, cells were seeded in 12-well plates and utilized
when approximately 50% confluent.
When requested, cells were incubated with inhibitors
30 minutes before challenge with IGF-1.vehicle IGF-1
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e growth factor-1 is mediated by ERK 1/2. (A) Western blot analysis
dy in membrane and cytosolic fractions prepared from serum-starved
indicated time intervals. A blot representative of at least three
represents densitometric analysis of three independent experiments.
. The increase of phospho-SK1 membrane content induced by IGF-1
myoblasts were pre-incubated for 30 minutes with ERK1/2 specific
minutes. Cell lysates were separated by SDS-PAGE and
s. A blot representative of at least three independent experiments is
K1 was normalized to β-actin and reported as mean± SEM of three
orylation in IGF-1-challenged cells was significantly reduced by U0126
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SK activity was measured as described by Olivera and
colleagues [17] with a few modifications, as described
previously [10]. Specific activity of SK was expressed as
picomoles of S1P formed per minute per milligram of
protein.Cell transfection
C2C12 cells were transfected with Lipofectamine RNAi-
MAX according to the manufacturer's instructions.
Briefly, Lipofectamine RNAiMAX was incubated with
siRNA in DMEM without serum and antibiotics at room
temperature for 20 minutes, and afterwards the lipid/
RNA complexes were added with gentle agitation to
C2C12 cells to a final concentration of 50 nM in serum
containing DMEM. After 24 h, cells were shifted to
DMEM without serum containing 1 mg/ml BSA and
then used for the experiments within 48 h from the be-
ginning of transfection. The specific gene knockdown
was evaluated by Western blot analysis or alternatively
by real-time PCR.Cellular fractionation
The medium of control and agonist-treated C2C12 cells
was removed and the cells were washed twice with ice-
cold PBS, scraped, and collected by centrifugation
(1000 × g). Cells were dispersed in a buffer solution con-
taining 10 mM HEPES, pH 7.4, 1 mM EGTA, 1 mM
EDTA, 250 mM sucrose, 5 mM NaN3, and protease inhi-
bitors (1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride,SK1
vehicle IGF-1
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Figure 3 Insulin-like growth factor-1 does not affect sphingosine kina
were incubated with DMEM containing 1 mg/ml bovine serum albumin (BS
(+) of 50 ng/ml insulin-like growth factor-1 (IGF-1). Top, aliquots of total cell
anti-sphingosine kinase (SK)1 and anti-SK2 antibodies. A representative blot
experiments. Data are the mean± SEM and are reported as protein expressio(AEBSF) 0.3 μM aprotinin, 10 μg/ml leupeptin and 10
μg/ml pepstatin) and disrupted in a Dounce homogenizer
(100 strokes). Lysates were centrifuged (10 minutes,
800 × g) and the resulting supernatant was centrifuged
again at 200,000 × g for 1 h to separate cytosolic and total
particulate fractions.Western blot analysis
C2C12 cells were lysed for 30 minutes at 4°C in a buffer
containing 50 mM Tris, pH 7.5, 120 mM NaCl, 1 mM
EDTA, 6 mM EGTA, 15 mM Na4P2O7, 20 mM NaF, 1%
Nonidet and protease inhibitor cocktail (1.04 mM
AEBSF, 0.08 μM aprotinin, 0.02 mM leupeptin, 0.04 mM
bestatin, 15 μM pepstatin A, and 14 μM E-64). To pre-
pare total cell lysates, cell extracts were centrifuged for
15 minutes at 10,000 × g at 4°C. Proteins from cell
lysates, cytosolic and membrane fractions were resus-
pended in Laemmli's SDS sample buffer. Samples were
subjected to SDS-PAGE for 90 minutes at 100 mA be-
fore transfer of proteins to PVDF membranes. Mem-
branes were incubated overnight with the primary
antibodies at 4°C and then with specific secondary anti-
bodies for 1 h at room temperature. Bound antibodies
were detected by chemiluminescence.Cell immunofluorescence
Cells were seeded on microscope slides, pre-coated with
2% gelatine, and then pre-incubated with SK specific in-
hibitor (10 μM SKI-2) before being challenged with 50
ng/ml IGF-1. After 72 h cells were fixed in 2%SK2
vehicle IGF-1
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lysates were used to perform Western analysis, using specific
is shown. Bottom, densitometric analysis of at least three independent
n normalized to β-actin, -fold change over control (set as 1).
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Figure 4 (See legend on next page.)
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Figure 4 The pro-myogenic effect of insulin-like growth factor-1 depends on sphingosine kinase engagement. (A) C2C12 myoblasts were
pre-incubated for 30 minutes with sphingosine kinase (SK) inhibitor (10 μM SKI-2) before being challenged with 50 ng/ml insulin-like growth
factor (IGF-1) for the indicated time intervals. The content of myogenin and caveolin-3 (cav-3) was analyzed by Western blotting in cell lysates.
Equally loaded protein was checked by expression of the non-muscle-specific β isoform of actin. A blot representative of four independent
experiments with analogous results is shown. The histograms represent band intensity of myogenin and cav-3 normalized to β-actin and reported
as mean± SEM of four independent experiments, -fold change over control (time 24 h, no addition; set as 1). The effect of IGF-1 in challenged
versus unchallenged cells at 24 h and 48 h on the expression levels of the myogenic markers was statistically significant by Student’s t test
(*P< 0.05). The effect of SK inhibition on basal expression levels of the myogenic markers in SKI-2 treated versus SKI-2 untreated cells was
statistically significant by Student’s t test (**P< 0.05). The effect of SK inhibition on IGF-1-induced expression of myogenin and cav-3 in challenged
cells (IGF-1 and SKI-2 added) versus control (IGF-1 added, no SKI-2) was statistically significant by Student’s t test (#P< 0.05). (B) C2C12 cells were
seeded on microscope slides and treated as described in A. Representative immunofluorescence images of C2C12 myoblasts treated for 72 h with
50 ng/ml IGF-1 stained with anti-myosin heavy chain (MHC) antibody and propidium iodide are shown. Fusion index and differentiation index
were calculated as described in the Methods section. Data are mean± SEM of three independent experiments. The effect of IGF-1 in challenged
versus unchallenged cells on fusion index and differentiation index was statistically significant by Student’s t test (*P< 0.05); fusion index and
differentiation index in IGF-1-challenged cells were significantly reduced by SKI-2 pre-incubation (Student’s t test #P< 0.05).
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lized in 0.1% Triton X-100-PBS for 30 minutes. Cells
were then blocked in 3% BSA for 1 h and incubated with
anti-MHC antibody for 2 h and fluorescein-conjugated
anti-mouse secondary antibody for 1 h. To stain nuclei,
the specimen was incubated with 50 μg/ml propidium
iodide in PBS for 15 minutes. Images were obtained
using a Leica SP5 laser scanning confocal microscope
(Leica Microsystems GmbH, Wetzlar, Germany) with a
40× objective. To quantify the differentiation and fusion
of C2C12 cells after treatment, we calculated the differ-
entiation index as the percentage of MHC-positive cells
above total nuclei and the fusion index as the average
number of nuclei in MHC-positive cells with at least
three nuclei above total number of nuclei, respectively.
Quantitative real-time reverse transcription PCR
Total RNA (2 μg), extracted with TRI reagent from
C2C12 myoblasts, was reverse transcribed using the
high capacity cDNA reverse transcription kit (Applied
Biosystems). The quantification of S1PR mRNA was
performed by real-time PCR employing TaqMan gene
expression assays. Each measurement was carried out
in triplicate, using the automated ABI Prism 7700 Se-
quence Detector System (Applied Biosystems) as
described previously [18], by simultaneous amplification
of the target sequence (S1P1 Mm00514644_m1, S1P2
Mm01177794_m1, S1P3 Mm00515669_m1, and S1P4
Mm00468695_s1; Applied Biosystems) together with the
housekeeping gene 18 S rRNA. Results were analyzed by
ABI Prism Sequence Detection System software, version
1.7 (Applied Biosystems). The 2-ΔΔCT method was applied
as a comparative method of quantification [19], and data
were normalized to ribosomal 18 S RNA expression.
Cell proliferation
Cell proliferation was determined by measuring [3H]
Thymidine incorporation; C2C12 cells were serum-starved for 24 h and then challenged with or without 50
ng/ml IGF-1 for 16 h. [3H]Thymidine (1 μCi/well) was
added for the last 1 h of incubation. Cells were washed
twice in ice-cold PBS before the addition of 500 μl of
10% trichloroacetic acid for 5 minutes at 4°C. Cells were
washed again in ice-cold PBS, and 250 μl of ethanol:ether
(3:1 v/v) was added to the insoluble material. Samples
were then lysed in 0.25 N NaOH for 1 h at 37°C. Incorp-
oration of [3 H]Thymidine was measured by scintillation
counting.Statistical analysis
Statistical analysis was performed using Student’s t test.
Graphical representations were performed using Prism
5.0 (GraphPad Software, San Diego, CA, USA). Densito-
metric analysis of the Western blot bands was performed
using imaging and analysis software Quantity One (Bio-
Rad Laboratories, Hercules, CA, USA).Results
Insulin-like growth factor-1 stimulates sphingosine kinase
in C2C12 myoblasts
To explore whether the SK/S1P axis is involved in IGF-1
biological action, we first examined whether the growth
factor was capable of regulating SK activity in C2C12
cells. Data illustrated in Figure 1A show that 50 ng/ml
IGF-1 stimulated SK activity. Indeed, the growth factor
rapidly and transiently increased SK activity, peaking at
10 minutes and returning to basal level at 60 minutes. In
agreement, as shown in Figure 1B, myoblast treatment
with 50 ng/ml IGF-1 was responsible for rapid and tran-
sient translocation of both enzyme isoforms, SK1 and
SK2, to membrane fraction that was appreciable within 1
minute of incubation, reached the maximal effect at 5
minutes and declined thereafter, thus enhancing the
amount of active form of the two enzymes with a favor-
able access to the hydrophobic substrate sphingosine.
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Figure 5 (See legend on next page.)
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Figure 5 The pro-myogenic effect of insulin-like growth factor-1 depends on sphingosine kinase-1 and sphingosine kinase-2
engagement. (A) C2C12 myoblasts, transfected with scrambled (SCR) or sphingosine kinase (SK)1-siRNA were challenged with 50 ng/ml
insulin-like growth factor-1 (IGF-1) for the last 24 h of transfection. Western analysis of SK1 and skeletal muscle marker proteins were performed in
cell lysates. Equally loaded protein was checked by expression of the non-muscle-specific β isoform of actin. A blot representative of three
independent experiments with analogous results is shown. The histograms represent band intensity of SK1, myogenin and caveolin-3 (cav-3)
normalized to β-actin and reported as mean± SEM of three independent experiments, -fold change over control (time 24 h, no addition; set
as 1). (B) Myoblasts transfected with SCR- or SK2-siRNA were treated and used as described in A. SK silencing in SK1- and SK2-siRNA transfected
cells versus SCR-siRNA transfected cells was statistically significant (*P< 0.05). The effect of SK downregulation on IGF-1-induced expression of
myogenin and caveolin-3 in IGF-1-challenged, SK-siRNA transfected cells versus control (IGF-1 added, SCR-siRNA transfection) was statistically
significant by Student’s t test (#P< 0.05).
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translocation of the enzyme to the plasma membrane
appears to be mediated by ERK1/2 phosphorylation at
Ser225 [15], Western blot analysis using a specific anti-
phospho-SK1 antibody was performed in myoblast sub-
cellular fractions following IGF-1 treatment. Data
reported in Figure 2A show that cell challenge with 50
ng/ml IGF-1 resulted in a rapid increase in the phos-
phorylation of membrane-associated SK1, already detect-
able at 5 minutes with a maximum at 10 minutes of
incubation. Interestingly, the kinetic of membrane trans-
location of phospho-SK1 was consistent with the time-
course of enzyme activation induced by IGF-1 (Figure 1).
Given the ability of IGF-1 to activate the ERK1/2 signal-
ing pathway through its receptor, we analyzed the in-
volvement of this pathway in the activation of SK1
induced by the growth factor. For this purpose, cells
were treated with 5 μM U0126, a specific pharmaco-
logical inhibitor of the ERK1/2 pathway, 30 minutes be-
fore IGF-1 challenge. Results presented in Figure 2B
show that the inhibition of the ERK1/2 pathway pre-
vented SK1 phosphorylation induced by 10 minutes
treatment with IGF-1, demonstrating that the activation
of SK1 induced by the growth factor was mediated by
ERK1/2.
We then investigated whether IGF-1 was also able to
regulate the protein content of SK1 and SK2. As illu-
strated in Figure 3, Western blot analysis shows that
myoblast treatment with 50 ng/ml IGF-1 for 24 h or 48 h
did not affect SK1 or SK2 protein levels, ruling out this
possibility.
Involvement of sphingosine kinase in the myogenic effect
of insulin-like growth factor-1
To confirm the ability of IGF-1 to promote myoblast dif-
ferentiation, the expression of skeletal muscle marker
proteins such as myogenin and caveolin-3, normally ab-
sent in immature myoblasts but strongly expressed in
differentiated cells, was determined by Western analysis.
Results presented in Figure 4A show that the expression
of myogenic markers in unchallenged serum-deprived
myoblasts was enhanced in a time-dependent manner, inagreement with the release of autocrine differentiation
factors [20,21]. As expected, myoblast treatment with 50
ng/ml IGF-1 strongly increased the expression of both
the myogenic markers at 24 and 48 h. The possible in-
volvement of SK in the myogenic effect of the growth
factor was then investigated. To this aim, C2C12 myo-
blasts were treated with SKI-2, a specific pharmaco-
logical inhibitor of SK, already successfully used to block
the enzymatic activity in these cells [10]. In agreement
with the established role of the SK/S1P axis in myogen-
esis [7,22], 30 minutes pre-incubation with 10 μM SKI-2
significantly decreased the protein content of myogenin
and caveolin-3 in unchallenged cells (Figure 4A). Inter-
estingly, cell treatment with the inhibitor completely
reversed the enhanced expression of the two myogenic
markers induced by IGF-1 at all the examined time-
intervals, suggesting a key role of SK in IGF-1-induced
myogenesis. In keeping with its well established pro-
myogenic action, IGF-1 (50 ng/ml) at 72 h incubation
significantly augmented fusion index and differentiation
index, but its biological response was completely pre-
vented by previous incubation with SKI-2 (Figure 4B).
These results demonstrate that the IGF-1-dependent
myogenic process strictly depends on the activation of
SK. To further assess the involvement of SK in the myo-
genic response evoked by IGF-1 in murine myoblasts,
SK isoforms were specifically knocked-down by employ-
ing siRNA technology. In accordance with previous
reports [10,22], specific siRNA treatment efficaciously
reduced basal expression levels of SK1 (Figure 5A). The
three-fold IGF-1-dependent increase of myogenin ex-
pression was totally abrogated when SK1 was downregu-
lated by RNA interference, while caveolin-3 content,
increased by the growth factor by approximately 3.5-fold,
was robustly decreased (approximately two-fold)
(Figure 5A). Furthermore, the myogenic effect of IGF-1
was also reduced when SK2 was downregulated by spe-
cific RNA interference (Figure 5B). Indeed, Figure 5B
shows that silencing of SK2 expression blunted the in-
crease of myogenin and caveolin-3 content elicited by 50
ng/ml IGF-1 by approximately 1.5-fold. The knocking
down experiments support a role for both SK isoforms
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Figure 6 (See legend on next page.)
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Figure 6 Role of sphingosine 1-phosphate receptors in insulin-like growth factor-1-induced differentiation of mouse myoblasts. C2C12
myoblasts, transfected with scrambled (SCR) or with specific siRNA for individual sphingosine 1-phosphate receptors (S1PR), incubated in the
absence (−) or in the presence (+) of 50 ng/ml insulin-like growth factor-1 (IGF-1) for the last 24 h of transfection, were checked for
downregulation by real-time PCR (left). Middle, Western analysis of skeletal muscle marker proteins was performed in cell lysates. Equally loaded
protein was checked by expression of the non-muscle-specific β isoform of actin. A blot representative of three independent experiments with
analogous results is shown. Right, densitometric analysis. The histograms represent band intensity of myogenin and caveolin-3 (cav-3) normalized
to β-actin and reported as mean± SEM of three independent experiments, -fold change over control (time 24 h, no addition; set as 1). The
effect of S1P2 downregulation on IGF-1-induced expression of myogenin and cav-3 in IGF-1-challenged, S1P2-siRNA transfected cells versus
IGF-1-challenged, SCR-siRNA transfected cells was statistically significant by Student’s t test (#P< 0.05); S1PR silencing was statistically significant in
S1PR-siRNA transfected cells versus SCR-transfected cells (*P< 0.05).
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reduced effectiveness of SK2 downregulation in compari-
son to SK1 in preventing the myogenic effect of the
growth factor suggests that the SK1 isoform plays a
dominant role.The pro-myogenic effect of insulin-like growth factor-1
depends on sphingosine 1-phosphate2 receptor
engagement
We have previously demonstrated that exogenous S1P
exerts pro-myogenic action in C2C12 cells via engage-
ment of the S1P2 receptor [7]. Since IGF-1 is able to in-
crease S1P biosynthesis by activating both SK1 and SK2,
and given that this event is crucial for the differentiating
action of the growth factor, we investigated whether the
myogenic action exerted by IGF-1 was mediated by S1P2
engagement in myoblasts. For this purpose, the expres-
sion of skeletal muscle marker proteins induced by 50
ng/ml IGF-1 was evaluated in myoblasts where S1P2 was
specifically downregulated by RNA interference. As
shown in Figure 6, siRNA directed against S1P2, which
significantly reduced the receptor expression, strongly
attenuated the enhancement of myogenin elicited by
IGF-1 (approximately three-fold) and abrogated the in-
crease of caveolin-3. Conversely, the downregulation of
the other receptor isoforms, S1P1, S1P3 or S1P4, by spe-
cific siRNA did not alter the myogenic effect of the
growth factor (Figure 6). The observed appreciable
stimulation of the expression of caveolin-3 in unchal-
lenged cells where S1P3 was downregulated (Figure 6)
was in agreement with the previously demonstrated anti-
myogenic action mediated by this receptor subtype [7].
Altogether, these data support the view that transactiva-
tion of S1P2 by IGF-1 is implicated in the myogenic ef-
fect of the growth factor in myoblasts.Sphingosine kinase/sphingosine 1-phosphate signaling
pathway is negatively implicated in the mitogenic effect
of insulin-like growth factor-1
Besides stimulating myogenesis, IGF-1 is also critically
implicated in the control of myoblast growth. Therefore,
we investigated whether the activation of the SK/S1Psignaling pathway mediated by IGF-1 was also implicated
in the mitogenic effect of the growth factor. Data pre-
sented in Figure 7A show that 50 ng/ml IGF-1 strongly
stimulated cell proliferation, determined by measuring
the incorporation of [3 H] Thymidine into DNA, con-
firming the reported mitogenic effect of the growth fac-
tor in these cells [12]. Interestingly, when myoblasts
were previously incubated with the specific pharmaco-
logical inhibitor of SK (SKI-2), the mitogenic effect of
IGF-1 was significantly enhanced, suggesting a negative
role of SK in modulating the proliferative response eli-
cited by the growth factor. To further support this find-
ing, individual SK isoforms were knocked-down by
specific siRNA treatment (Figure 7B, insert). In accord-
ance with the results obtained employing the pharmaco-
logical inhibitor SKI-2, data presented in Figure 7B
demonstrate that knocking-down of SK1, as well as SK2,
strongly increased the mitogenic effect elicited by IGF-1
by 90% and 50%, respectively.
To establish whether the mechanism by which the SK/
S1P axis inhibits IGF-1-induced cell proliferation relies
on receptor engagement, labelled thymidine incorpor-
ation experiments were performed in cells where individ-
ual S1PR were specifically knocked down by siRNA
technology (Figure 8A). Results illustrated in Figure 8B
clearly show that downregulation of S1P1 or S1P3 by
RNA interference significantly enhanced DNA synthesis
induced by 50 ng/ml IGF-1, whereas cell transfection
with siRNA that specifically downregulated S1P2 or S1P4
did not impair the mitogenic effect of the growth factor.
These data demonstrate that enhanced biosynthesis of
S1P, due to SK1 and SK2 activation induced by IGF-1, is
responsible for the engagement of S1P1 and S1P3 and is
negatively implicated in the mitogenic effect of the
growth factor.Sphingosine 1-phosphate lyase is not implicated in the
insulin-like growth factor-1 biological role in skeletal
muscle
Finally, since cell response to IGF-1 was found to depend
on S1P intracellular levels, we investigated whether SPL,
responsible for the irreversible degradation of S1P, is
vehicle IGF-1
0
2
8
10
12
14
SCR siRNA
SK2 siRNA
#
Re
la
tiv
e 
[3 H
] t
hy
m
id
in
e
 
in
co
rp
o
ra
tio
n
vehicle IGF-1
0
2
6
8
10
12
14
16
18
SCR siRNA
SK1 siRNA
#
Re
la
tiv
e 
[3 H
] t
hy
m
id
in
e
 
in
co
rp
o
ra
tio
n
vehicle IGF-1
0
2
5
10
15
20
Ctrl
SKI-2
#
*
Re
la
tiv
e 
[3 H
] t
hy
m
id
in
e
 
in
co
rp
o
ra
tio
n
A
B
Figure 7 Role of sphingosine kinase in the mitogenic effect of
insulin-like growth factor-1. (A) Serum-starved C2C12 myoblasts
were pre-incubated for 30 min in the presence or absence of 1 μM SKI-2
before being stimulated with 50 ng/ml insulin-like growth factor-1 (IGF-1)
for 16 h. [3 H]Thymidine (1 μCi/well) was added during the last hour of
incubation. [3 H]Thymidine incorporation in untreated cells was
29893± 1584 dpm. Results are reported as -fold change over control
(vehicle, no addition; set as 1). Data are mean± SEM of at least three
independent experiments performed in triplicate. The mitogenic effect
of IGF-1 in challenged versus unchallenged cells was statistically
significant by Student’s t test (*P< 0.05). The effect of SK inhibition on
the mitogenic effect of IGF-1 in challenged cells versus control (no SKI-2,
IGF-1 added) was statistically significant by Student’s t test (#P< 0.05).
(B) Scrambled (SCR) or specific SK1- (upper panel) or SK2-siRNA (lower
panel) transfected C2C12 cells were treated or not treated with 50 ng/
ml IGF-1 for 16 h. [3 H]Thymidine (1 μCi/well) was added during the last
hour of incubation. [3 H]Thymidine incorporation was 20781±785 dpm
in control cells (untreated SCR-transfected cells). Results are reported as -
fold change over control (SCR siRNA, no addition; set as 1). Data are
mean±SEM of at least four independent experiments performed in
triplicate. The effect of SK downregulation on IGF-1-induced [3 H]
Thymidine incorporation in IGF-1-challenged, SK1- and SK2-siRNA
transfected cells versus control (IGF-1 added, SCR-siRNA transfection)
was statistically significant by Student's t test (#P< 0.05). Insert: cell
extracts from C2C12 myoblasts transfected with SCR-, SK1-siRNA or SK2-
siRNA were employed for Western analysis using anti-SK1 or anti-SK2
antibodies. Equally loaded protein was checked by expression of β-actin.
A blot representative of at least four independent experiments with
analogous results is shown. Band intensity of SK1 or SK2 was normalized
to β-actin and reported as -fold change over control (SCR siRNA, no
addition; set as 1).
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Figure 8 Role of sphingosine 1-phosphate receptors in the
mitogenic effect of insulin-like growth factor-1. (A) Quantitative
mRNA analysis was performed in C2C12 myoblasts transfected with
non-specific scrambled (SCR) siRNA or with siRNA specific for
sphingosine 1-phosphate receptors (S1PR); the content of
housekeeping gene 18 S rRNA was analyzed in parallel. Results are
expressed as -fold changes according to the 2−ΔΔCT method,
utilizing each receptor subtype in cells transfected with SCR-siRNA as
a calibrator. Data are mean± SEM of three independent experiments
performed in triplicate. S1PR silencing in S1PR-siRNA transfected cells
versus SCR-siRNA transfected cells was statistically significant
(*P< 0.05). (B) Serum-starved C2C12 myoblasts transfected with
unspecific SCR-siRNA, or with specific siRNA for individual S1PR, were
stimulated with 50 ng/ml insulin-like growth factor 1 (IGF-1) for 16 h.
[3 H]Thymidine (1 μCi/well) was added during the last hour of
incubation. [3 H]Thymidine incorporation was 19643± 844 dpm in
control cells (untreated SCR-transfected cells). Results are reported as
-fold change over control (SCR siRNA, no addition; set as 1). Data are
mean± SEM of at least three independent experiments performed in
triplicate. The effect of S1P1 and S1P3 downregulation on the IGF-1-
induced [3H]Thymidine incorporation in IGF-1-challenged, S1P1- and
S1P3-siRNA transfected cells versus IGF-1-challenged, SCR-siRNA
transfected cells was statistically significant by Student's t test
(#P< 0.05).
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Western analysis data presented in Figure 9A show that
treatment with 50 ng/ml IGF-1 did not affect SPL pro-
tein content in C2C12 myoblasts. In the same figure it is
shown that the increased expression of skeletal muscle
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Figure 9 (See legend on next page.)
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Figure 9 Sphingosine 1-phosphate lyase is not involved in insulin-like growth factor-1 biological action in C2C12 myoblasts. (A) C2C12
myoblasts, transfected with scrambled (SCR) or sphingosine 1-phosphate lyase (SPL)-siRNA, were incubated in the absence (−) or in the presence
(+) of 50 ng/ml insulin-like growth factor-1 (IGF-1) for the last 24 h of transfection. Western analysis of SPL and skeletal muscle marker proteins
was performed in cell lysates. Equally loaded protein was checked by expression of the non-muscle-specific β isoform of actin. A blot
representative of three independent experiments with analogous results is shown. The histograms represent band intensity of SPL, myogenin and
caveolin-3 (cav-3) normalized to β-actin and reported as mean± SEM of three independent experiments, -fold change over control (time 24 h, no
addition; set as 1). SPL silencing in SPL-siRNA transfected cells versus SCR-siRNA transfected cells was statistically significant by Student’s t test
(*P< 0.05). The effect of SPL downregulation on basal expression levels of myogenin and cav-3 in SPL-siRNA transfected, unchallenged cells
versus SCR-siRNA transfected, unchallenged cells was statistically significant by Student’s t test (#P< 0.05). (B) Myoblasts transfected with unspecific
SCR-siRNA or with specific SPL-siRNA were treated or not treated with 50 ng/ml IGF-1 for 16 h. [3 H]Thymidine (1 μCi/well) was added during the
last hour of incubation. [3 H]Thymidine incorporation was 21781 ± 993 dpm in control cells (untreated SCR-transfected cells). Results are reported
as -fold change over control (SCR siRNA, no addition; set as 1). Data are mean± SEM of at least three independent experiments performed in
triplicate. Insert: cell extracts from C2C12 myoblasts transfected with SCR- and SPL-siRNA were employed for Western analysis using anti-SPL
antibodies. Equally loaded protein was checked by expression of β-actin. A blot representative of at least four independent experiments with
analogous results is shown. Band intensity of SPL was normalized to β-actin and reported as -fold change over control (SCR siRNA, no addition;
set as 1).
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affected by specific downregulation of SPL by RNA inter-
ference, ruling out the involvement of this enzyme in the
control of the IGF-1 myogenic effect. It is interesting to
note that knocking-down of SPL enhanced basal expres-
sion levels of the myogenic markers by approximately
two-fold, in favor of the participation of the enzyme in
the regulation of intracellular levels of S1P, whose myo-
genic effect has been previously demonstrated [7,22].
We then investigated the role of SPL in IGF-1-induced
DNA synthesis. For this purpose, labelled thymidine in-
corporation experiments were performed in cells where
SPL had been specifically downregulated by employing
siRNA technology. Data presented in Figure 9B clearly
show that cell transfection with siRNA that specifically
downregulated SPL (Figure 9B, insert) did not impair the
mitogenic effect of IGF-1, demonstrating that SPL does
not participate in the IGF-1-directed regulation of S1P
metabolism.
Discussion
The IGF-1 signaling pathway plays a key role in the
regulation of skeletal muscle growth, in differentiation,
and in the maintaining of tissue homeostasis. Intri-
guingly, this growth factor stimulates two key processes
such as myoblast proliferation and differentiation which
are mutually exclusive events during myogenesis [12].
The results presented here for the first time demonstrate
that the SK/S1P signaling pathway is involved in the
regulation of the biological action exerted by IGF-1. This
finding is crucial for the timely regulation of cell prolif-
eration and differentiation. Indeed, experimental evi-
dence is provided that activation of SK followed by
transactivation of S1P2 elicited by the growth factor is
required for its pro-myogenic action whereas the parallel
engagement of S1P1 and S1P3 reduces its mitogenic ef-
fect. Notably, the IGF1-induced SK/S1P axis appears toexhibit the unique property of regulating two opposite
biological effects elicited by IGF-1 in myoblasts - trans-
ducing its myogenic response on one side and inhibiting
its mitogenic effect on the other - therefore acting as an
efficacious switch to stop proliferation and triggering dif-
ferentiation through the concomitant activation of indi-
vidual S1PR subtypes.
Previously we have demonstrated in these cells that the
final biological outcome of PDGF, which plays a crucial
role in skeletal muscle, depends on SK/S1P axis activa-
tion [11]. Indeed, the activation of SK1 induced by PDGF
resulted in the transactivation of S1P1, responsible for
the chemotactic response elicited by PDGF and also for
the negative regulation of its mitogenic effect. Despite
the overlapping role of the SK/S1P axis in inhibiting the
mitogenic effect of both PDGF and IGF-1, we show here
that the negative regulation of IGF-1-induced prolifera-
tion, beside being dependent on S1P1, relies also on S1P3
engagement. Moreover, in this study, we have established
that the IGF-1 myogenic effect is dependent on the en-
gagement of S1P2, which has been already shown to be
coupled to the pro-differentiating activity of exogenous
and endogenous S1P in these cells [7,22].
Interestingly, here we provide the first evidence of the
involvement of SK2 in S1P inside-out signaling in myo-
blasts. Indeed SK2, similarly to the SK1 isoform, was
found to be required for transmitting the pro-myogenic
effect of IGF-1, highlighting a key role of this enzyme
isoform in skeletal muscle biology. In this regard, the
parallel regulation of mitogenesis and migration elicited
by PDGF was found to rely exclusively on the specific ac-
tivation of SK1 [11]. SK1 and SK2 have different devel-
opmental expression, adult tissue distribution and
subcellular localization patterns. Such differences are in
line with the concept that, although the two enzymes use
the same substrate and generate the same product, they
can mediate distinct biological events. SK1 is almost
Bernacchioni et al. Skeletal Muscle 2012, 2:15 Page 15 of 16
http://www.skeletalmusclejournal.com/content/2/1/15universally associated with the induction of cell survival
and proliferation [23], whereas SK2 overexpression sup-
presses cell growth and enhances apoptosis [24]. Studies
performed in mesangial cells supported the pro-
apoptotic role of SK2, demonstrating that SK2-null cells
are more resistant to staurosporine-induced apoptosis
than wild-type or SK1-null cells [25]. Our findings cor-
roborate the notion that SK isoforms may instead have
overlapping functions. Indeed, data obtained by preincu-
bation with the pharmacological inhibitor SKI-2 that
does not distinguish between the two SK isoforms, and
by specific silencing of SK1 or SK2 isoforms demonstrate
the involvement of both enzyme isoforms in the pro-
myogenic effect of IGF-1. In accordance, it has been re-
cently reported that SK1 and SK2 are equally required
for epidermal growth factor-induced migration of breast
cancer cells [26] and TGFβ-induced migration and inva-
sion of esophageal cancer cells [27].
Data previously reported in the literature sustain the
existence of a functional cross-talk between IGF-1 and
S1P signaling pathways. IGF-1 was shown to elicit
ERK1/2 activation by stimulating SK1-dependent trans-
activation of S1P1 even though the biological effect of
S1P-dependent ERK1/2 activation was not addressed
[28,29]. In this study, for the first time, we identified the
involvement of the SK/S1PR axis in the biological action
of IGF-1, that intriguingly in its molecular mechanism
of action implies ERK1/2-dependent phosphorylation of
SK1.
It is worth noting that exogenous S1P has been previ-
ously reported to counteract the chemotactic action
exerted by IGF-1 in myoblasts via ligation of S1P2 [8].
The involvement reported in this paper of the SK/S1P
axis in mediating IGF-1 biological effects is not in con-
strast with the previous finding. Indeed, it appears that
the selective spatial control of S1P formation inside myo-
blasts following stimulation with different cues is crucial
for the generation of a specific biochemical response. In
this regard, we recently demonstrated that endogenous
S1P that is formed in response to PDGF challenge stimu-
lates cell motility via S1P1 [11], whereas exogenous S1P
was previously found to inhibit motility of the same cell
type acting through S1P2 [8]. Moreover, we recently
demonstrated that, in C2C12 myoblasts, the S1P signal-
ing pathway, which physiologically accounts for myo-
genic differentiation via S1P2, is redirected by the
cytokine TGFβ to act primarily via the pro-fibrotic S1P3.
Indeed, consequently to TGFβ treatment, S1P3 then
becomes the prevailing expressed receptor, thus promot-
ing myoblast transdifferentiation to myofibroblasts [9].
Finally, we investigate the possible involvement of SPL
in skeletal muscle biology. A previous study performed
by Herr and colleagues [30] demonstrated that normal
S1P catabolism is required for Drosophila muscledevelopment, given that SPL-null mutants exhibited pat-
tern abnormalities in the dorsal longitudinal flight mus-
cles of the adult thorax. Moreover, SPL was recently
identified as a potential therapeutic target for ischemia-
reperfusion injury of the heart [31]. Using a genetic SPL
knock-out mouse model and a chemical inhibitor, Band-
huvula and colleagues [31] demonstrated that ischemia
caused the activation of SPL in cardiac tissue resulting in
the reduction of the levels of S1P, thus promoting cardio-
myocyte apoptosis. For the first time, we have demon-
strated in this paper that mouse myoblasts express SPL.
Furthermore, we provide evidence that this enzyme con-
tributes to the regulation of intracellular levels of the
pro-myogenic S1P, as knocking-down of the enzyme
resulted in the upregulation of the basal expression levels
of myogenic markers. This is in agreement with the con-
cept that, in this experimental condition, S1P intracellu-
lar levels are enhanced and consequently the mediated-
promyogenic action is potentiated [7,22]. However, from
this study, SPL appears to be disengaged from IGF-1-
mediated biological effects as its specific downregulation
did not affect either myogenesis or proliferation induced
by the growth factor.
Taking into account the different S1PR patterns
expressed in satellite cells and murine myoblasts, and
considering that exogenous S1P is mitogenic in satellite
cells whereas it acts as an anti-mitogenic and pro-
differentiating cue in myoblasts [6,7], it will be interest-
ing to further investigate whether the individuated cross-
talk between the IGF-1 and S1P signaling pathway
observed here also takes place in satellite cells and med-
iates a specific IGF-1-induced biological response
Conclusions
Collectively, our findings support the notion that the SK/
S1P axis, via the engagement of S1PR, exhibits the
unique ability to regulate two opposite biological effects
elicited by IGF-1 in myoblasts - transducing its myogenic
response on one side and inhibiting its mitogenic effect
on the other. These results increase our knowledge on
the mechanism by which IGF-1 regulates skeletal muscle
regeneration.
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